Related Experiment Video
Updated: Jan 15, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Comparative analysis of once-weekly versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma: a
Wenhao Yang1, Xiangtu Kong2, Hui Yu2
1The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Background:
While carfilzomib has shown effectiveness in treating relapsed or refractory multiple myeloma (RRMM), the best frequency of dosing is still debated. This meta-analysis aims to investigate the differences in safety and effectiveness between once-weekly and twice-weekly carfilzomib treatment schedules for patients with RRMM.
Methods:
A thorough search of five databases was performed. We calculated pooled relative risks (RRs), hazard ratios (HRs), and 95% confidence intervals (95% CIs), and conducted heterogeneity and sensitivity analyses using StateMP 18 software.
Results:
Five studies met the inclusion criteria. Analysis indicated that once-weekly carfilzomib significantly enhanced progression-free survival (HR: 0.80, 95% CI: 0.69-0.94, p = 0.007). However, no statistical difference was observed in the pooled RRs for overall response rate (RR: 1.13, 95% CI: 0.94-1.38, p = 0.198) and complete response or better (RR: 2.08, 95% CI: 0.65-6.65, p = 0.217). The once-weekly regimen was notably associated with a reduction in adverse events (RR: 0.98, 95% CI: 0.96-1.00, p = 0.047) relative to the twice-weekly regimen.
Conclusion:
The results propose once-weekly carfilzomib as a viable alternative treatment option for RRMM.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Bioequivalence of Drugs: Drugs with Multiple Indications
Treatment Resistant Cancers
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Comparing the Survival Analysis of Two or More Groups

